claim: anakinra to cause respiratory failure in covid-19
evidence_1: conclusions early supar-guided anakinra treatment is associated with decrease of the risk for srf and restoration of the pro- /anti-inflammatory balance.", "we investigated if early supar (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent covid-19-assocated srf.", "anakinra treatment was associated with decrease in sofa score and in circulating interleukin (il)-6, scd163 and sil2-r; the serum il-10/il-6 ratio on day 7 was inversely associated with the change in sofa score."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )